Seegene and Springer Nature Partner to Advance PCR Diagnostics with New Grants

Seegene, a leading biotechnology firm, and Springer Nature, a prominent academic publisher, have launched the "Nature Awards MDx Impact Grants" to drive innovation in syndromic PCR diagnostic assays. This initiative aims to foster external innovation in the development of new diagnostic tests for infectious diseases. Global research teams are invited to submit proposals by December 2, 2024, with the goal of creating cutting-edge multiplex PCR technologies.

The grants represent a significant investment in advancing diagnostic capabilities through open innovation. By supporting the commercialization of multiplex PCR technology, this collaboration seeks to enhance the availability and effectiveness of diagnostic tests for various human infectious diseases. The Nature Awards will oversee the application and evaluation processes, ensuring that projects align with clinical needs and scientific advancements.

Selected projects will be announced in August 2025, reflecting the initiative’s commitment to addressing pressing health challenges through innovative diagnostic solutions. The collaboration between Seegene and Springer Nature underscores a shared vision of leveraging academic research and industry expertise to achieve breakthroughs in molecular diagnostics.